A Phase II Study of CCI-779 in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 09 Jun 2014
At a glance
- Drugs Rituximab (Primary) ; Temsirolimus (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 03 Dec 2013 Status changed from active, no longer recruiting to completed.
- 03 Dec 2013 Actual end date changed from 1 Sep 2009 to 1 Apr 2011 as reported by ClinicalTrials.gov.
- 06 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.